Journal Mobile Options
Table of Contents
Vol. 53, No. 1, 2006
Issue release date: February 2006

Dopamine Receptor D1 Gene –48A/G Polymorphism Is Associated with Bipolar Illness but Not with Schizophrenia in a Polish Population

Dmitrzak-Weglarz M. · Rybakowski J.K. · Slopien A. · Czerski P.M. · Leszczynska-Rodziewicz A. · Kapelski P. · Kaczmarkiewicz-Fass M. · Hauser J.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Dysregulation of dopaminergic neurotransmission has been implicated in the etiology of major psychoses. The dopamine D1 receptor (DRD1) plays a role in some brain functions and mechanisms of psychotropic drugs. Therefore, the DRD1 gene makes a good candidate gene for molecular genetic studies in schizophrenia and bipolar affective disorder. In the present study, the –48A/G polymorphism of the DRD1 gene was estimated in patients with schizophrenia (n = 407) or bipolar affective disorder (n = 380), and in healthy controls (n = 399). No association was found between the polymorphism studied and schizophrenia, either in the whole group of patients or in subgroups divided by gender, age at onset or predominance of positive or negative symptoms. A statistical trend was obtained for an association between this polymorphism and bipolar affective disorder (p = 0.059 for genotypes, p = 0.073 for alleles). The G/G genotype and G allele were significantly more frequent in patients with bipolar disorder, type II (p = 0.016 for genotypes, p = 0.008 for alleles), especially in the women subgroup (p = 0.054 for genotypes, p = 0.024 for alleles). An association between the G/G genotype and bipolar affective disorder with disease onset after 18 years of age was also found (p = 0.022). These data suggest that the –48A/G polymorphism of the DRD1 gene may be involved in the etiology of bipolar disorder in a Polish population.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV: Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 2004;174:3–16.
  2. Wirkner K, Krause T, Koles L, Thummler S, Al-Khrasani M, Illes P: D1 but not D2 dopamine receptors or adrenoceptors mediate dopamine-induced potentiation of N-methyl-d-aspartate currents in the rat prefrontal cortex. Neurosci Lett 2004;372:89–93.
  3. Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S: Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry 2004;161:1620–1625.
  4. Grandy DK, Zhou QY, Allen L, Litt R, Magenis RE, Civelli O, Litt M: A human D1 dopamine receptor gene is located on chromosome 5 at q35.1 and identifies an EcoRI RFLP. Am J Hum Genet 1990;47:828–834.
  5. Minowa MT, Minowa T, Monsma FJ, Sibley DR, Mouradian MM: Characterization of the 5′ flanking region of the human D1A dopamine receptor gene. Proc Natl Acad Sci USA 1992;89:3045–3049.
  6. Mouradian MM, Minowa MT, Minowa T: Promoter structure of the human gene coding for the D1A dopamine receptor. Adv Neurol 1993;60:343–345.
  7. Nothen MM, Korner J, Lannfelt L, Sokoloff P, Schwartz J-C, Lanczik M, Reitschel M, Cichon S, Kramer R, Fimmers R, Moller H-J, Beckmann H, Propping P, Grandy DK, Civelli OB.F. OD: Lack of association between schizophrenia and alleles of the dopamine D1, D2, D3 and D4 receptor loci. Psychiatry Genet 1993;3:89–94.

    External Resources

  8. Dollfus S, Campion D, Vasse T, Preterre P, Laurent C, d’Amato T, Thibaut F, Mallet J, Petit M: Association study between dopamine D1, D2, D3, and D4 receptor genes and schizophrenia defined by several diagnostic systems. Biol Psychiatry 1996;40:419–421.
  9. Cichon S, Nothen MM, Erdmann J, Propping P: Detection of four polymorphic sites in the human dopamine D1 receptor gene (DRD1). Hum Mol Genet 1994;3:209.
  10. Liu Q, Sobell JL, Heston LL, Sommer SS: Screening the dopamine D1 receptor gene in 131 schizophrenics and eight alcoholics: identification of polymorphisms but lack of functionally significant sequence changes. Am J Med Genet 1995;60:165–171.
  11. Kojima H, Ohmori O, Shinkai T, Terao T, Suzuki T, Abe K: Dopamine D1 receptor gene polymorphism and schizophrenia in Japan. Am J Med Genet 1999;88:116–119.
  12. Cichon S, Nothen MM, Stober G, Schroers R, Albus M, Maier W, Rietschel M, Korner J, Weigelt B, Franzek E, Wildenauer D, Fimmers R, Propping P: Systematic screening for mutations in the 5′-regulatory region of the human dopamine D1 receptor (DRD1) gene in patients with schizophrenia and bipolar affective disorder. Am J Med Genet 1996;67:424–428.
  13. Ni X, Trakalo JM, Mundo E, Macciardi FM, Parikh S, Lee L, Kennedy JL: Linkage disequilibrium between dopamine D1 receptor gene (DRD1) and bipolar disorder. Biol Psychiatry 2002;52:1144–1150.
  14. De Luca V, Severino G, Ni X, Piccardi P, de Baltomeis A, Squassina A, Muscettola G, Kennedy JL, Del Zompo M: Haplotype association study between DRD1 gene and parasuicide in bipolar disorder: analysis of two samples from Canada and Sardinia. Eur Psychiatry 2005;20:S186–206.
  15. Garner C, McInnes LA, Service SK, Spesny M, Fournier E, Leon P, Freimer NB: Linkage analysis of a complex pedigree with severe bipolar disorder, using a Markov chain Monte Carlo method. Am J Hum Genet 2001;68:1061–1064.
  16. Shink E, Morissette J, Villeneuve A, Bordeleau L, Rochette D, Gagne B, Laprise C, Plante M, Barden N: Support for the presence of bipolar disorder susceptibility loci on chromosome 5: heterogeneity in a homogeneous population in Quebec. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1273–1277.
  17. Severino G, Congiu D, Serreli C, De Lisa R, Chillotti C, Del Zompo M, Piccardi MP: A48G polymorphism in the D1 receptor genes associated with bipolar I disorder. Am J Med Genet 2005, 134B, pp 37–38.

    External Resources

  18. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, American Psychiatric Press, 1996.
  19. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
  20. Hauser J, Leszczynska-Rodziewicz A, Samochowiec J, Ostapowicz A, Czerski P, Jaracz J, Suwalska A, Horodnicki J, Rybakowski J: The association study of functional polymorphism of the monoamine oxidase A gene promoter in patients witch affective disorders. Arch Psychiatry Psychother 2002;4:9–15.
  21. Hauser J, Leszczynska A, Samochowiec J, Czerski PM, Ostapowicz A, Chlopocka M, Horodnicki J, Rybakowski JK: Association analysis of the insertion/deletion polymorphism in serotonin transporter gene in patients with affective disorder. Eur Psychiatry 2003;18:129–132.
  22. Pantazopoulos H, Stone D, Walsh J, Benes FM: Differences in the cellular distribution of D1 receptor mRNA in the hippocampus of bipolars and schizophrenics. Synapse 2004;54:147–155.
  23. Rybakowski JK, Borkowska A, Czerski PM, Kapelski P, Dmitrzak-Weglarz M, Hauser J: An association study of dopamine receptors polymorphisms and the Wisconsin Card Sorting Test in schizophrenia. J Neural Transm 2005 DOI: 10.1007/s00702-005-0292-6.
  24. Potkin SG, Basile VS, Jin Y, Masellis M, Badri F, Keator D, Wu JC, Alva G, Carreon DT, Bunney WE Jr, Fallon JH, Kennedy JL: D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry 2003;8:109–113.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50